We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. Pays $812.5 Million for 650,000 More Doses of Eli Lilly’s COVID-19 Antibody
U.S. Pays $812.5 Million for 650,000 More Doses of Eli Lilly’s COVID-19 Antibody
The U.S. government is exercising its option for an additional 650,000 doses of Eli Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) for $812.5 million, following the drug’s Emergency Use Authorization (EUA) in November for mild-to-moderately ill COVID-19 patients at high risk.